Join

Compare · AEMD vs BSX

AEMD vs BSX

Side-by-side comparison of Aethlon Medical Inc. (AEMD) and Boston Scientific Corporation (BSX): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AEMD and BSX operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BSX is the larger of the two at $72.39B, about 15253.9x AEMD ($4.7M).
  • Over the past year, AEMD is down 99.2% and BSX is down 51.3% - BSX leads by 47.9 points.
  • BSX has been more active in the news (12 items in the past 4 weeks vs 4 for AEMD).
  • BSX has more recent analyst coverage (25 ratings vs 2 for AEMD).
PerformanceAEMD-99.20%BSX-51.31%
2025-06-09+0.00%2026-06-08
MetricAEMDBSX
Company
Aethlon Medical Inc.
Boston Scientific Corporation
Price
$2.03+2.53%
$48.71+0.31%
Market cap
$4.7M
$72.39B
1M return
-10.57%
-13.91%
1Y return
-99.20%
-51.31%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NYSE
IPO
News (4w)
4
12
Recent ratings
2
25
AEMD

Aethlon Medical Inc.

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

BSX

Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Latest AEMD

Latest BSX